Correlation Between Morgan Stanley and Propanc Biopharma

Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Propanc Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Propanc Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Morgan Stanley Direct and Propanc Biopharma, you can compare the effects of market volatilities on Morgan Stanley and Propanc Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Propanc Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Propanc Biopharma.

Diversification Opportunities for Morgan Stanley and Propanc Biopharma

-0.45

Correlation Coefficient

Morgan Stanley  Propanc Biopharma

Very good diversification

The 3 months correlation between Morgan and Propanc is -0.45. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley Direct and Propanc Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Propanc Biopharma and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley Direct are associated (or correlated) with Propanc Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Propanc Biopharma has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Propanc Biopharma go up and down completely randomly.

Pair Corralation between Morgan Stanley and Propanc Biopharma

Given the investment horizon of 90 days Morgan Stanley is expected to generate 16.96 times less return on investment than Propanc Biopharma. But when comparing it to its historical volatility, Morgan Stanley Direct is 21.5 times less risky than Propanc Biopharma. It trades about 0.04 of its potential returns per unit of risk. Propanc Biopharma is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  0.03  in Propanc Biopharma on September 28, 2024 and sell it today you would lose (0.01) from holding Propanc Biopharma or give up 33.33% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	95.24%
Values	Daily Returns

Morgan Stanley Direct  vs.  Propanc Biopharma

Morgan Stanley Direct

Risk-Adjusted Performance

10 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley Direct are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite quite weak fundamental indicators, Morgan Stanley may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Propanc Biopharma

Risk-Adjusted Performance

7 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Propanc Biopharma are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak fundamental indicators, Propanc Biopharma sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Morgan Stanley and Propanc Biopharma

The main advantage of trading using opposite Morgan Stanley and Propanc Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Propanc Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Propanc Biopharma will offset losses from the drop in Propanc Biopharma's long position.

The idea behind Morgan Stanley Direct and Propanc Biopharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.